Study of Regorafenib and Sildenafil for Advanced Solid Tumors

ClinicalTrials.gov ID: NCT02466802

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02466802. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 8:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase I Study of Regorafenib and Sildenafil for Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a phase 1 study of sildenafil in combination with regorafenib in patients with progressive advanced solid tumors. A modified 3+3 dose escalation design will be conducted for the dose escalation of the treatment combination: additional patients will be enrolled at the MTD until a total of 12 patients have been treated at the MTD.

Study identification

NCT ID: NCT02466802
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Virginia Commonwealth University; Other
Enrollment: 32 participants

Conditions and interventions

Conditions

Solid Tumor

Interventions

Regorafenib Drug
Sildenafil Citrate Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 1, 2015 (Actual)
Primary completion: Jan 28, 2019 (Actual)
Completion: Jan 28, 2019 (Actual)
Last update posted: Feb 20, 2020

2015 – 2019

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Virginia Commonwealth University/Massey Cancer Center	Richmond	Virginia	23298	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02466802, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 20, 2020 · Synced Nov 13, 2026